Prescribing guide
Dawnzera (donidalorsen)Dosing every 4 or 8 weeks, missed doses, autoinjector storage, enrollment and prior authorization criteria for hereditary angioedemaFor prescribers and their offices treating hereditary angioedema (HAE): what the pharmacy needs before it ships, what the prior authorization wants documented, the titration and the monitoring the label requires.
Dispensing gate
No REMS; Patient Enrollment and Prescription Form by fax or an e-prescription, prior authorization, patient contact with the Ionis Every Step Specialty Pharmacy before it ships, and injection training before the first dose.
Example PA threshold
Cigna example: age 12 or older, HAE type I or II with functional C1-INH under 50% and low C4, both documented; allergist, immunologist or HAE specialist; Haegarda and Takhzyro tried first on employer plans; no concomitant preventive HAE therapy.
Monitoring
No scheduled lab monitoring in the label; watch for hypersensitivity including anaphylaxis; platelet reductions and ALT, AST and GGT increases were seen in trials; not recommended in moderate or severe hepatic impairment.
Support line
Ionis Every Step, 1-844-444-4305, Monday to Friday 8 AM to 8 PM ET; enrollment form fax 1-877-558-0007; commercial copay as little as $0 per prescription; Quick Start free drug during the insurance approval process; one-dose Free Trial Program for new patients.
Give your patient their plan
A one-page handout for starting Dawnzera, in plain language: what the first fill waits on, the first dates, who will call and the symptoms to report, with blank lines for the start date and your office's number. The link opens the patient's full first 90 days page, where their dates become calendar entries.
trialfriend.com/p/dawnzeraBefore the first fill: REMS, labs and enrollment
The steps that the pharmacy, the REMS or the drugmaker's program will wait on, in the order they usually need to happen. A first fill of a specialty drug most often stalls on one of these rather than on the plan.
| Step | What it requires | Source |
|---|---|---|
| No REMS | Dawnzera does not appear in the FDA REMS data files, and the label sets no REMS and no boxed warning. | FDA REMS list |
| Enrollment and Prescription Form | Complete the DAWNZERA Patient Enrollment and Prescription Form and fax it to 1-877-558-0007. Ionis says Dawnzera can also be prescribed through the EHR or the DAWNZERA Direct online companion. | HCP starting patients |
| Prescription fields | 80mg/0.8mL single-dose autoinjector, NDC 71860-103-01: every 4 weeks, quantity 1, refills 11 or other; or every 8 weeks, quantity 1, refills 5 or other. Prescriber signature, no stamps. Alternatively e-prescribe to CoAssist Pharmacy. New York providers also submit an electronic prescription. | Enrollment form |
| Clinical information | ICD-10-CM D84.1 or other. The form asks for attack frequency, severity and location, C1-INH antigenic and functional levels, serum C4, previous and current medications with responses, and drug allergies. | Enrollment form |
| Quick Start | The form enrolls insured patients automatically unless the opt-out box is checked. Free drug during the insurance approval process once all prior authorization information is received. Not for uninsured patients or after a final coverage determination; not billable to any insurer. | Enrollment form |
| Free Trial Program | A one-time, one-dose supply at no charge for patients new to Dawnzera, prescribed only through the form, not through the EHR. Open to US and Puerto Rico patients including Medicare and Medicaid; requires Ionis Every Step consent; shipped to the home address, no refills. | Enrollment form |
| Patient consent | The patient signs the Patient Authorization and Consent section in the office, enrolls online at DAWNZERA.com/Enroll, or calls 1-844-444-4305. A Welcome Kit and a Patient Education Manager call to schedule administration training follow. | HCP Ionis Every Step |
| Coverage | Typically covered under the pharmacy benefit. Ionis Every Step confirms benefits and plan criteria and tells the office which forms are needed. The exception or PA package goes to the plan electronically, by a link Ionis can provide, or verbally by phone. | HCP starting patients |
| Shipment | The Ionis Every Step Specialty Pharmacy calls the patient to set up delivery. Dawnzera is not shipped until the patient speaks with the pharmacy about potential cost and delivery; advise saving 1-844-444-4305. | HCP starting patients |
| Injection training | Train the patient or caregiver on preparation and subcutaneous technique with the autoinjector before treatment starts. Dawnzera is intended for self-administration or administration by a caregiver. | FDA label |
| Appeals and reauthorization | After a denial, review the plan's reason, schedule a peer-to-peer review promptly and draft a Letter of Appeal; Ionis posts a sample letter and a coverage guide. DAWNZERA AuthASSIST supports reauthorization. | HCP starting patients |
Prior authorization criteria and what to document
One public policy as the example: Cigna, September 15, 2026. Approval approved a year at a time. Renewal asks for HAE type I or II and a favorable response, such as fewer, milder or shorter attacks. This version took effect September 15, 2026 and made no criteria changes. It cites the August 2025 prescribing information, and the label on DailyMed is marked revised September 2025 with the same dose. The step through Haegarda and Takhzyro was added for employer plans in March 2026. Other plans set their own criteria. It is here as an example, not as a rule.
| Element | What the policy asks | In the chart | Source |
|---|---|---|---|
| Age | 12 years of age or older | Date of birth on the request | Cigna policy |
| Diagnosis | HAE type I or II, with functional C1-INH below 50% of normal at baseline | C1-INH functional lab report with reference range [documentation required] | Cigna policy |
| C4 | Serum C4 below normal at baseline | C4 lab report with reference range [documentation required] | Cigna policy |
| Exclusion | HAE with normal C1-INH (type III) does not satisfy the diagnosis requirement | Lab results that show C1-INH deficiency | Cigna policy |
| Prescriber | Prescribed by or in consultation with an allergist/immunologist or a physician who specializes in HAE or related disorders | Specialty on the request, or the consult note | Cigna policy |
| Preferred products | Employer plans: the patient has tried both Haegarda and Takhzyro, each of which requires prior authorization, or is currently receiving Dawnzera | Medication history on the request | Cigna policy |
| Dosing | 80mg subcutaneously not more frequently than every 4 weeks; other doses reviewed case by case | Regimen on the request | Cigna policy |
| Combination | Concomitant long-term prophylaxis with other HAE preventives (Andembry, Cinryze, Haegarda, Orladeyo, Takhzyro) is not medically necessary; on-demand and short-term procedural use is allowed | Medication list on the request | Cigna policy |
| Continuation | Diagnosis of HAE type I or II [documentation required] and, per the prescriber, a favorable response such as fewer, less severe or shorter attacks; approval for 1 year | Attack log against pre-prophylaxis baseline | Cigna policy |
Dawnzera dosing and titration
| When | Label | Source |
|---|---|---|
| Recommended dose | 80mg subcutaneously every 4 weeks, in adult and pediatric patients 12 years of age and older. | FDA label |
| Every-8-week option | 80mg subcutaneously every 8 weeks may be considered. The label states no criteria for selecting it. OASIS-HAE attack rate reduction against placebo: 81% on q4wks (95% CI 65 to 89), 55% on q8wks (95% CI 22 to 74). | FDA label |
| Missed dose | Administer as soon as possible, then resume at the recommended dosing frequency, every 4 or every 8 weeks, from the date of the most recently administered dose. | FDA label |
| Presentation | 80mg/0.8mL single-dose autoinjector, 1 per carton, NDC 71860-103-01. Clear, colorless to yellow solution. | FDA label |
| Administration | Abdomen or upper thigh; the back of the upper arm only when a caregiver or healthcare provider injects. Remove from the refrigerator 30 minutes before injecting; no other warming methods. Do not use if cloudy, discolored or containing particulates. | FDA label |
| Storage | 2°C to 8°C (36°F to 46°F) in the original carton. May be kept at room temperature up to 30°C (86°F) in the original carton for up to 6 weeks; discard if not used within that time. Do not freeze or expose to heat; protect from direct light. | FDA label |
| Pharmacokinetics and pharmacodynamics | Median Tmax about 2 hours; terminal half-life about 1 month. Mean prekallikrein reduction 48% at week 4; trough reductions at week 24 of 73% on q4wks and 47% on q8wks. | FDA label |
| Age limits | Not established under 12 years. Trials did not include enough patients 65 and older to tell whether they respond differently. | FDA label |
Monitoring the Dawnzera label requires
| When | What | What the label says to do with it | Source |
|---|---|---|---|
| Any time | Hypersensitivity, including anaphylaxis | Reported in clinical trials, with generalized rash, dyspnea, chest pain and peri-oral swelling; discontinue and institute appropriate therapy for a serious reaction | FDA label |
| Any time | Injection site reactions | 24% on q4wks, 4% on q8wks and 5% on placebo in OASIS-HAE; all mild and nonserious, most resolving without treatment | FDA label |
| OASIS-HAE | Platelet count | Mean change at week 25 of 9.6% lower on q4wks, 7.9% lower on q8wks and 1.4% lower on placebo; no count below 50,000/mm3 and no major bleeding linked to low platelets across 3 studies; no monitoring schedule specified | FDA label |
| Clinical trials | ALT, AST and GGT | Increases from baseline, generally below 3x ULN and stabilizing; discontinuations for liver test increases were infrequent; no monitoring schedule specified | FDA label |
| Before starting | Hepatic function | No adjustment in mild impairment; not studied and not recommended in moderate or severe impairment (total bilirubin above 1.5x ULN regardless of AST) | FDA label |
| Before starting | Renal function | No adjustment in mild impairment (eGFR 60 to under 90); not studied in moderate or severe impairment or end-stage renal disease | FDA label |
| Immunogenicity | Anti-drug antibodies | 20% on q4wks and 22% on q8wks in OASIS-HAE; 35% on q4wks in the open-label extension; in general no effect found on PD, safety or efficacy, but the label calls the data inconclusive | FDA label |
| Postmarketing requirement | Drug-induced liver injury | The approval letter requires completion of the 4-year and 3-year open-label extension trials to evaluate the potential for drug-induced liver injury, with a final report due September 2027 | FDA letter |
| Renewal | Attack frequency, severity or duration | Cigna approves 1 year at a time; continuation needs a favorable response according to the prescriber | Cigna policy |
Dawnzera drug interactions and contraindications
| Label category | Agents and what the label says | Source |
|---|---|---|
| Other drugs | No clinical drug-drug interaction studies have been performed; the label has no drug interactions section. | FDA label |
| CYP enzymes and transporters | In vitro, donidalorsen is not a CYP substrate, inhibitor or inducer, is not a substrate or inhibitor of transporters, and does not interact with highly plasma protein bound drugs. | FDA label |
| Linker metabolite M8 | A substrate of CYP3A4, BSEP and OATP1B3 and an inhibitor of MATE1 in vitro; not a CYP inhibitor or inducer. | FDA label |
| Other HAE prophylaxis | OASIS-HAE required stopping other prophylactic HAE medications, except androgens and tranexamic acid, before entry. All patients could use rescue medications for breakthrough attacks. | FDA label |
| QT interval | No clinically significant QTc prolongation at 80mg every 4 weeks. | FDA label |
| Pregnancy and lactation | No human pregnancy data; no adverse developmental effects in mice at up to 5 times the MRHD, and donidalorsen did not cross the placenta. No human milk data; excreted in mouse milk. | FDA label |
Why a first fill stalls, and the fix
- Prior authorization pending or deniedCigna asks for a functional C1-INH level under 50% of normal and a low C4 level, each with lab documentation. It also wants an allergist, immunologist or HAE specialist, and a patient aged 12 or older. The office sends both lab reports.
- The plan wants other medicines tried firstCigna's employer plans ask that the patient has tried both Haegarda and Takhzyro, or is already receiving Dawnzera. Other plans set their own lists.
- HAE with normal C1-INHCigna's policy says HAE with normal C1-INH, also called type III, does not meet its diagnosis requirement. That holds for first approvals and for renewals.
- Another preventive medicine at the same timeCigna lists Dawnzera used with other preventive HAE medicines, such as Andembry, Cinryze, Haegarda, Orladeyo or Takhzyro, as not medically necessary. Medicines that treat an attack, or prevent one around a procedure, are allowed.
- A dose the plan will not coverCigna approves 80mg no more often than every 4 weeks. Other doses go to case-by-case review by a Cigna clinician.
- An appeal after a denialIonis tells offices to read the plan's reason for the denial and ask for a peer-to-peer review quickly. Its prescriber site offers a sample Letter of Appeal, and Ionis Every Step helps with appeals at 1-844-444-4305. The office files the appeal.
- The medicine has not shippedIonis says Dawnzera will not ship until you speak with the Ionis Every Step Specialty Pharmacy about cost and delivery. The pharmacy calls from 1-844-444-4305, and Ionis suggests saving that number in your phone.
- A copay you cannot payWith commercial insurance, Ionis Every Step says you may pay as little as $0 for each prescription. People who use Medicare, Medicaid, TRICARE, VA or other government programs for medicine costs are excluded. Ionis also runs a Patient Assistance Program for people without affordable insurance coverage.
- A gap in insurance coverageIonis says its Bridge program can give a short-term supply at no cost during a temporary gap in commercial insurance. You have to be eligible, and terms apply. Ionis Every Step answers questions at 1-844-444-4305.
Ionis Every Step
- A Patient Education Manager who explains what happens after the prescription and teaches you how to use Dawnzera
- Work with your doctor and your insurance plan to help get Dawnzera covered
- A copay program where a commercially insured patient may pay as little as $0 out of pocket for each prescription
- No copay help for anyone who uses Medicare, Medicaid, TRICARE, Department of Defense, VA or other government programs for medicine costs
- Delivery to your door from the Ionis Every Step Specialty Pharmacy
- DAWNZERA Direct, a digital companion for refill scheduling, status updates and a swell diary
- Quick Start, a shipment of free medicine if insurance coverage is delayed Ionis Every Step brochure
- Bridge, a short-term supply at no cost during a temporary gap in commercial insurance, for people who are eligible Ionis Every Step brochure
- A Patient Assistance Program that provides Dawnzera at no cost to eligible people without affordable insurance, with a financial application and a yearly reapplication Ionis Every Step brochure
- A Free Trial Program, a one-time single dose at no charge for people new to Dawnzera, including people with Medicare and Medicaid Enrollment form
Questions prescribers' offices ask about Dawnzera
What is the Dawnzera dose?
80mg subcutaneously every 4 weeks in patients 12 and older, per the September 2025 label (section 2.1); 80mg every 8 weeks may be considered. The label gives no criteria for choosing the longer interval. In OASIS-HAE the attack rate was 81% lower than placebo on q4wks and 55% lower on q8wks.
Does Dawnzera have a REMS or required lab monitoring?
No. The September 2025 label has no REMS, no boxed warning and no scheduled lab monitoring, and Dawnzera is not in the FDA REMS data. The one contraindication is prior serious hypersensitivity, and the one warning is hypersensitivity including anaphylaxis (section 5.1). Use is not recommended in moderate or severe hepatic impairment (section 8.7).
What does the label say about a missed dose?
Administer the missed dose as soon as possible, then resume at the recommended frequency from the date of the most recently administered dose, per the September 2025 label (section 2.1). Section 17 specifies that this means every 4 weeks or every 8 weeks from that dose.
How is the Dawnzera autoinjector stored?
At 2°C to 8°C (36°F to 46°F) in the original carton, or at room temperature up to 30°C (86°F) in the original carton for up to 6 weeks, per the September 2025 label (section 16). Discard if not used within 6 weeks at room temperature. Do not freeze, do not expose to heat, and protect from direct light.
What do insurers ask for to approve Dawnzera?
The Cigna policy shown here, effective September 15, 2026, asks for age 12 or older, HAE type I or II with functional C1-INH under 50% of normal and a low C4, both documented, and an allergist, immunologist or HAE specialist. Employer plans also require a trial of both Haegarda and Takhzyro unless the patient is already on Dawnzera. Approval is for 1 year at 80mg no more often than every 4 weeks.
Free email alert
Get an email when the Dawnzera label changes
One email the day the FDA revises the Dawnzera prescribing information, with a summary of what changed. No trial alerts or newsletter, and you can stop anytime.
Label changes for Dawnzera only, usually a few a year and some years none. Stop anytime. We never share your email. Privacy policy
Sources
- DailyMed - DAWNZERA- donidalorsen injection, solution (prescribing information revised 9/2025, Patient Information issued 08/2025, Instructions for Use approved 08/2025), Ionis Pharmaceuticals Inc., via DailyMed, 2026-08-31.
- Approved Risk Evaluation and Mitigation Strategies (REMS), FDA, 2026-11-11.
- Sign Up for Ionis Every Step™ | DAWNZERA™ (donidalorsen), Ionis Pharmaceuticals, 2026-11-11.
- Ionis Every Step brochure: Let's take this step by step, together (US-DONI-2500102 v1.0 08/2025), Ionis Pharmaceuticals, 2026-11-11.
- Getting Started With DAWNZERA™ (donidalorsen) (US-DONI-2500216 v1.0 08/2025), Ionis Pharmaceuticals, 2026-11-11.
- DAWNZERA Patient Enrollment and Prescription Form (US-DONI-2500004 v2.0 08/2025), Ionis Pharmaceuticals, 2026-11-11.
- Getting Patients Started on DAWNZERA™ (donidalorsen), Ionis Pharmaceuticals, 2026-11-11.
- Ionis Every Step™ | DAWNZERA™ (donidalorsen), Ionis Pharmaceuticals, 2026-11-11.
- Hereditary Angioedema - Dawnzera, Drug Coverage Policy IP0761, Cigna, 2026-09-15.
- NDA 219407 approval letter, Dawnzera (donidalorsen) solution for injection, FDA, 2025-08-21.
A reference drawn from the August 31, 2026 label, the drugmaker's published program and one public insurer policy shown as an example, checked on November 11, 2026. Labels and policies change; the label on DailyMed and the plan's current policy govern. Trial Friend is not a medical provider. It reports what these documents say and does not judge whether a drug is safe or right for any patient; that is the prescriber's decision. Not a substitute for the prescribing information.